Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Acurx Pharmaceuticals, Inc.ACXP · Entity 8195 | Director | April 20, 2026 | April 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Acurx Pharmaceuticals, Inc.
Report date April 20, 2026 · Filed April 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.36 · Expires 2036-04-20 | Direct | 37,100 |
Reported balance
After 2026-04-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-20 · Grant · Acquired 37,100 · Balance 37,100 F1: On April 20, 2026 (the "Grant Date"), the Reporting Person was granted stock options to purchase 37,100 shares of the Issuer's common stock. These options vest in 36 equal monthly installments commencing on the Grant Date. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 20, 2026 (the "Grant Date"), the Reporting Person was granted stock options to purchase 37,100 shares of the Issuer's common stock. These options vest in 36 equal monthly installments commencing on the Grant Date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
PLx Pharma Inc.
Report date January 17, 2017 · Filed April 20, 2017
Section 16 reporting ended · disclosed 2017-04-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.80 · Expires 2022-01-17 | Direct | 183,332 |
Reported balance
After 2017-01-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-01-17 · Grant · Acquired 183,332 · Balance 183,332 F1: Options to purchase shares of common stock vest as follows: options to purchase 91,666 shares of common stock vested on January 17, 2017; options to purchase 3,819 shares of common stock vest monthly in each of the 23 months after the date of grant and options to purchase 3,829 shares of common stock will vest on the 24th month anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Options to purchase shares of common stock vest as follows: options to purchase 91,666 shares of common stock vested on January 17, 2017; options to purchase 3,819 shares of common stock vest monthly in each of the 23 months after the date of grant and options to purchase 3,829 shares of common stock will vest on the 24th month anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 20, 2026 Filed Apr 22, 2026 16:18 UTC | Acurx Pharmaceuticals, Inc. ACXP · Entity 8195 | GrantStock Option · Derivative | 37,100 | $0.00 Strike: $2.36 | $0.00 |
DisclosureSEC source: 0001104659-26-046836 · tm2612397-3_4seq1.xml · derivative · entry 1 DELUCCIA ROBERT J · CIK 0001127423 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,100 Underlying: Common Stock · 37,100 shares Expires 2036-04-20 F1 · derivative.exercise_date: On April 20, 2026 (the "Grant Date"), the Reporting Person was granted stock options to purchase 37,100 shares of the Issuer's common stock. These options vest in 36 equal monthly installments commencing on the Grant Date. Read SEC document |
| February 05, 2025 Filed Feb 6, 2025 17:45 UTC | Acurx Pharmaceuticals, Inc. ACXP · Entity 8195 | GrantStock Option · Derivative | 250,000 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001104659-25-010179 · tm255798-1_4seq1.xml · derivative · entry 1 DELUCCIA ROBERT J · CIK 0001127423 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2035-02-05 F1 · derivative.exercise_date: On February 5, 2025, the Reporting Person was granted stock options to purchase 250,000 shares of the Issuer's common stock. These options vest immediately. Read SEC document |
| January 06, 2025 Filed Jan 8, 2025 16:30 UTC | Acurx Pharmaceuticals, Inc. ACXP · Entity 8195 | PurchaseWarrants for Common Stock · Derivative | 49,261 | $0.00 Strike: $0.90 | $0.00 |
DisclosureSEC source: 0001104659-25-002050 · tm252665-2_4seq1.xml · derivative · entry 3 DELUCCIA ROBERT J · CIK 0001127423 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,261 Underlying: Common Stock · 49,261 shares Expires 2030-01-07 F2 · shares: Acquired in a concurrent private placement of warrants by Acurx Pharmaceuticals, Inc. in connection with the registered direct offering of common stock. Read SEC document |
| January 06, 2025 Filed Jan 8, 2025 16:30 UTC | Acurx Pharmaceuticals, Inc. ACXP · Entity 8195 | PurchaseCommon Stock | 49,261 | $1.02 | $49,999.92 |
DisclosureSEC source: 0001104659-25-002050 · tm252665-2_4seq1.xml · nonDerivative · entry 1 DELUCCIA ROBERT J · CIK 0001127423 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,010,196 F1 · shares: Acquired at the offering price in a registered direct offering of common stock by Acurx Pharmaceuticals, Inc. Read SEC document |
| February 23, 2024 Filed Apr 3, 2024 21:55 UTC | Acurx Pharmaceuticals, Inc. ACXP · Entity 8195 | GrantStock Option · Derivative | 250,000 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001104659-24-043291 · tm2411025-1_4seq1.xml · derivative · entry 1 DELUCCIA ROBERT J · CIK 0001127423 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2034-02-22 F1 · derivative.exercise_date: On February 23, 2024 (the "Grant Date"), the Reporting Person was granted stock options to purchase 250,000 shares of the Issuer's common stock. These options vest in 36 equal monthly installments commencing on the Grant Date. This transaction is late due to an inadvertent administrative error and not any error of the Reporting Person. Read SEC document |
| January 03, 2024 Filed Jan 4, 2024 16:26 UTC | Acurx Pharmaceuticals, Inc. ACXP · Entity 8195 | Exercise / conversionWarrants for Common Stock · Derivative | 19,737 | $0.00 Strike: $3.55 | $0.00 |
DisclosureSEC source: 0001104659-24-001375 · tm242052-2_4seq1.xml · derivative · entry 6 DELUCCIA ROBERT J · CIK 0001127423 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,737 shares Expires 2024-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2024 Filed Jan 4, 2024 16:26 UTC | Acurx Pharmaceuticals, Inc. ACXP · Entity 8195 | Exercise / conversionCommon Stock | 19,737 | $3.55 | $70,066.35 |
DisclosureSEC source: 0001104659-24-001375 · tm242052-2_4seq1.xml · nonDerivative · entry 4 DELUCCIA ROBERT J · CIK 0001127423 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 960,935 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 22, 2023 Filed Jan 4, 2024 16:26 UTC | Acurx Pharmaceuticals, Inc. ACXP · Entity 8195 | GiftCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-001375 · tm242052-2_4seq1.xml · nonDerivative · entry 3 DELUCCIA ROBERT J · CIK 0001127423 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 941,198 F1 · kind: These transactions involved bona fide gifts by the Reporting Person of an aggregate of 110,000 shares of the Issuer's common stock to certain of the Reporting Person's family members who do not share the Reporting Person's household. The Reporting Person disclaims beneficial ownership of the securities held by such family members, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. These transactions are late due to an inadvertent administrative error and not any error of the Reporting Person. Read SEC document |
| December 12, 2023 Filed Jan 4, 2024 16:26 UTC | Acurx Pharmaceuticals, Inc. ACXP · Entity 8195 | GiftCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-001375 · tm242052-2_4seq1.xml · nonDerivative · entry 2 DELUCCIA ROBERT J · CIK 0001127423 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 971,198 F1 · kind: These transactions involved bona fide gifts by the Reporting Person of an aggregate of 110,000 shares of the Issuer's common stock to certain of the Reporting Person's family members who do not share the Reporting Person's household. The Reporting Person disclaims beneficial ownership of the securities held by such family members, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. These transactions are late due to an inadvertent administrative error and not any error of the Reporting Person. Read SEC document |
| February 13, 2023 Filed Feb 24, 2023 16:30 UTC | Acurx Pharmaceuticals, Inc. ACXP · Entity 8195 | GrantStock Option · Derivative | 130,000 | $0.00 Strike: $3.41 | $0.00 |
DisclosureSEC source: 0001104659-23-025330 · tm237745-1_4seq1.xml · derivative · entry 1 DELUCCIA ROBERT J · CIK 0001127423 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2033-02-12 F1 · derivative.exercise_date: On February 13, 2023 (the " Grant Date"), the Reporting Person was granted stock options to purchase 130,000 shares of the Issuer's common stock. These options vest in 36 equal monthly installments commencing on the Grant Date. This transaction is late due to an inadvertent administrative error and not any error of the Reporting Person. Read SEC document |
| July 27, 2022 Filed Jul 29, 2022 17:02 UTC | Acurx Pharmaceuticals, Inc. ACXP · Entity 8195 | PurchaseWarrants for Common Stock · Derivative | 19,737 | $0.00 Strike: $3.55 | $0.00 |
DisclosureSEC source: 0001104659-22-084316 · tm2222169-2_4seq1.xml · derivative · entry 4 DELUCCIA ROBERT J · CIK 0001127423 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,737 Underlying: Common Stock · 19,737 shares Expires 2028-01-27 Read SEC document |
| July 27, 2022 Filed Jul 29, 2022 17:02 UTC | Acurx Pharmaceuticals, Inc. ACXP · Entity 8195 | PurchaseWarrants for Common Stock · Derivative | 19,737 | $0.00 Strike: $3.55 | $0.00 |
DisclosureSEC source: 0001104659-22-084316 · tm2222169-2_4seq1.xml · derivative · entry 3 DELUCCIA ROBERT J · CIK 0001127423 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,737 Underlying: Common Stock · 19,737 shares Expires 2024-01-27 Read SEC document |
| July 27, 2022 Filed Jul 29, 2022 17:02 UTC | Acurx Pharmaceuticals, Inc. ACXP · Entity 8195 | PurchaseCommon Stock | 19,737 | $3.80 | $75,000.60 |
DisclosureSEC source: 0001104659-22-084316 · tm2222169-2_4seq1.xml · nonDerivative · entry 1 DELUCCIA ROBERT J · CIK 0001127423 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,051,198 Read SEC document |
| December 02, 2021 Filed Jan 4, 2024 16:26 UTC | Acurx Pharmaceuticals, Inc. ACXP · Entity 8195 | GiftCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-001375 · tm242052-2_4seq1.xml · nonDerivative · entry 1 DELUCCIA ROBERT J · CIK 0001127423 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,011,198 F1 · kind: These transactions involved bona fide gifts by the Reporting Person of an aggregate of 110,000 shares of the Issuer's common stock to certain of the Reporting Person's family members who do not share the Reporting Person's household. The Reporting Person disclaims beneficial ownership of the securities held by such family members, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. These transactions are late due to an inadvertent administrative error and not any error of the Reporting Person. Read SEC document |
| November 19, 2021 Filed Nov 22, 2021 16:05 UTC | Acurx Pharmaceuticals, Inc. ACXP · Entity 8195 | PurchaseCommon Stock | 5,034 | $4.90 | $24,671.63 |
DisclosureSEC source: 0001104659-21-142473 · tm2133703-2_4seq1.xml · nonDerivative · entry 1 DELUCCIA ROBERT J · CIK 0001127423 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,031,461 F1 · price: The price reflects the average purchase price of the shares of common stock purchased. These shares of common stock were purchased in multiple transactions at prices ranging from $4.886 to $4.961 per share of common stock. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares of common stock purchased at each price. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 16:05 UTC | Acurx Pharmaceuticals, Inc. ACXP · Entity 8195 | GrantStock Option · Derivative | 500,000 | $0.00 Strike: $6.18 | $0.00 |
DisclosureSEC source: 0001104659-21-089392 · tm2121425-1_4seq1.xml · derivative · entry 2 DELUCCIA ROBERT J · CIK 0001127423 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2031-06-30 F2 · derivative.exercise_date: On July 1, 2021 (the "Employment Agreement Grant Date"), the Reporting Person was granted stock options to purchase 500,000 shares of the Issuer's common stock in connection with the Reporting Person's service as the Issuer's Executive Chairman pursuant to the Reporting Person's employment agreement. 25% of the stock options granted became vested and exercisable on the Employment Agreement Grant Date and 75% of the stock options shall become vested and exercisable as of each monthly anniversary from the Employment Agreement Grant Date, such that all stock options shall be fully vested and exercisable by July 1, 2024. Read SEC document |
| June 29, 2021 Filed Jul 6, 2021 16:05 UTC | Acurx Pharmaceuticals, Inc. ACXP · Entity 8195 | GrantStock Option · Derivative | 350,000 | $0.00 Strike: $6.26 | $0.00 |
DisclosureSEC source: 0001104659-21-089392 · tm2121425-1_4seq1.xml · derivative · entry 1 DELUCCIA ROBERT J · CIK 0001127423 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2031-06-28 F1 · derivative.exercise_date: On June 29, 2021 (the "June Grant Date"), the Reporting Person was granted stock options to purchase 350,000 shares of the Issuer's common stock. 40% of the stock options granted became vested and exercisable on the June Grant Date and 60% of the stock options shall become vested and exercisable as of each monthly anniversary from the June Grant Date, such that all stock options shall be fully vested and exercisable by June 29, 2024. This transaction is late due to an inadvertent administrative error and not any error of the Reporting Person. Read SEC document |
| January 17, 2017 Filed Apr 20, 2017 06:15 UTC | PLx Pharma Inc. DPRX · Entity 129056 | GrantOptions · Derivative | 183,332 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001144204-17-021120 · v464463_4.xml · derivative · entry 1 DELUCCIA ROBERT J · CIK 0001127423 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,332 Underlying: Common Stock · 183,332 shares Expires 2022-01-17 F1 · derivative.exercise_date: Options to purchase shares of common stock vest as follows: options to purchase 91,666 shares of common stock vested on January 17, 2017; options to purchase 3,819 shares of common stock vest monthly in each of the 23 months after the date of grant and options to purchase 3,829 shares of common stock will vest on the 24th month anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.